Considering depression as a risk marker for incident coronary disease

Similar documents
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

How would you manage Ms. Gold

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Supplement materials:

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

CVD risk assessment using risk scores in primary and secondary prevention

Preventive Cardiology Scientific evidence

Cardiac Screening with Electrocardiography, Stress Echocardiography, or Myocardial Perfusion Imaging

CVD Prevention, Who to Consider

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

CONTRIBUTING FACTORS FOR STROKE:

Blood Pressure LIMBO How Low To Go?

Supplementary Online Content

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Statistical Fact Sheet Populations

Lipid Management 2013 Statin Benefit Groups

Diabetes Mellitus: A Cardiovascular Disease

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

EuroPrevent 2010 Fatal versus total events in risk assessment models

HYPERTENSION: UPDATE 2018

The University of Mississippi School of Pharmacy

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

Conflicts of Interest: None. Aspirin, primary prevention and USPSTF. Primary prevention of ASCVD is important

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

1. Which one of the following patients does not need to be screened for hyperlipidemia:

NHFA CONSENSUS STATEMENT ON DEPRESSION IN PATIENTS WITH CORONARY HEART DISEASE

Using the New Hypertension Guidelines

Identification of subjects at high risk for cardiovascular disease

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

EUROACTION A model for secondary and primary preventive care to achieve 25 by 25

Population models of health impact of combination polypharmacy

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People

Cardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital

Models of preventive care in clinical practice to achieve 25 by 25

MINNEAPOLIS September 12, 2012 Medtronic, Inc. (NYSE: MDT) today announced findings

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes.

Classes of recommendations

NEW GUIDELINES FOR CHOLESTEROL

Appendix J: Cost-effectiveness analysis blood pressure monitoring for confirming a diagnosis of hypertension (new 2011)

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

The Clinical Unmet need in the patient with Diabetes and ACS

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?

Comparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes

Misperceptions still exist that cardiovascular disease is not a real problem for women.

REFERENCE CODE GDHCER PUBLICAT ION DATE JULY 2014 ACUTE CORONARY SYNDROME (ACS) - EPIDEMIOLOGY FORECAST TO 2023

A logical approach to planning health care services in relation to need Dr Christopher A Birt University of Liverpool

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS

Cholesterol Management Roy Gandolfi, MD

Guidelines on cardiovascular risk assessment and management

CVD risk calculation

Environmental. Vascular / Tissue. Metabolics

Cardiovascular Complications of Diabetes

Treating Hypertension in Individuals with Diabetes

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

High Intensity Interval Exercise Training in Cardiac Rehabilitation

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

Hypertension Management Controversies in the Elderly Patient

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH

Causes of Poor BP control Rates

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS

Cardiac Patients Psychosocial Needs. Cardiac Patients Psychosocial Needs

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

Treatment to reduce cardiovascular risk: multifactorial management

Diabetes, Diet and SMI: How can we make a difference?

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

No relevant financial relationships

Heart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

J-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial

Atherosclerotic Disease Risk Score

J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018

Blood Pressure Targets in Diabetes

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

The Gender Divide Women, Men and Heart Disease February 2017

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Lipid Panel Management Refresher Course for the Family Physician

Economically efficient approaches to address chronic disease in developing countries

Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal

HYPERTENSION AND HEART FAILURE

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

2. Morbidity. Incidence

Transcription:

Considering depression as a risk marker for incident coronary disease Dr Adrienne O'Neil Senior Research Fellow Melbourne School of Population & Global Health The University of Melbourne & Visiting Fellow Laboratory of Behaviour Science, Stanford University

Coronary Disease in women CVD Number 1 killer of women in Australia United States United Kingdom South Africa Brazil Globally 1 Kills more women than all cancers, tuberculosis, HIV/AIDS, malaria combined 1 No longer viewed as male disease 1 World Heart Federation

Depression in Australian women Almost half of Australian adults 45% (7.3 million people) will have a mental disorder in their lifetime Depression more common in women: 1 in 5 (compared with 1 in 8 men) will experience depression at some stage of their lives. National Survey of Mental Health and Wellbeing (NSMHWB)

Relationship between depression & CHD Depression & CHD highly comorbid 15-20% of myocardial infarct (MI) patients report major depression; ~20% mild-moderate symptoms Post MI, depression increases risk of: morbidity mortality more frequent angina poor health service utilisation poor medication adherence May be reactionary to MI, but it is more complicated than that

Does depression precede heart disease?

What do the experts say? Depression should be elevated as risk factor for poor prognosis after MI but.. Need to clarify the role of depression as a potential risk factor for incident CHD

Recommendations. This approach may lead to: undue worry about the risk of CHD by individuals diagnosed with depression or over-diagnosis & over-treatment of depression In light of identified methodological shortcomings and the inconsistent findings reported we suggest that there is as yet no convincing evidence that depression is an independent causal risk factor for CHD. Stampfer HG, Hince DA, Dimmitt SB. Depression as a risk factor for coronary heart disease how strong is the evidence? O J Psych 2012; 2: 284-291

Study setting Total & female population of 259,013 & 132,124, respectively. Geelong (45 mins west of Melbourne) in South East Australia Well suited to epidemiological research Populations from a range of social, cultural and geographical settings

Does any depressive disorder identified at baseline independently predict CHD in women? Study Design

Study Measurements Exposure: Primary/secondary diagnosis of depressive disorder Data extracted from Geelong hospitals between 1993 and 2011 on: Primary outcome: Cardiac death Non-fatal Myocardial Infarction Coronary intervention. Secondary outcome Any cardiac event (un/stable angina, cardiac event not otherwise defined)

Results: Regression analyses n=860 adj. OR 95% CI Baseline Depression (unadjusted) 2.39 (1.19, 4.82)* Baseline Depression (adjusted Model 1) ^ 3.22 (1.45, 6.93)* Baseline Depression (adjusted Model 2) & 3.28 (1.36, 7.90)* ^typical risk factors; & (a)typical risk factors Results slightly weaker when expanding outcome to include Depression did not predict number of CHD events O Neil et al. (2016) Journal of Affective Disorders. http://dx.doi.org/10.1016/j.jad.2016.02.029

Conclusions Validate the host of other studies in this area indicating depression is a risk factor for incident CHD Adds to the evidence base for AHA consideration What does this mean for identification, prevention & treatment?

Example: Risk Assessment Framingham Risk Equation Incorporates 6 variables to assess patients % CHD risk over 10 years: Age HDL cholesterol Total cholesterol Systolic BP Smoking status Taking BP medication

Framingham Heart Study Limitations: Underestimates risk of subclinical CHD among asymptomatic women Considers only traditional risk factors Omitting less conventional risk factors, like depression is a serious deficiency affecting accuracy

Risk factors for heart attack Social isolation Stress Common Mental Disorders: anxiety, depression Yusuf S et al. INTERHEART: case-control study. Lancet. 2004;364:937-52.

Geelong Osteoporosis Study Aim: to determine accuracy of augmented FRE that includes depression as a predictor Barwon residents randomly selected from electoral rolls Women (20-94 years) BASELINE: Smoking, SBP, Total, HDL lipids, medication for BP 10 years: Psychiatric interview (age of onset) Retrospective data linkage with hospital records (CHD events by adjudication panel; BL to 10 years)

Results Age, BP Medication and depression at baseline significant predictors

New Risk Equation for Women Better overall accuracy true positives, at small increase in false positive rate. Original Framingham Risk Equation (solid line), Augmented to include depression (dashed) over 10-year O Neil, et al (Preventive Medicine, In Press)

Conclusions Depression appears a independent risk factor for CHD in women Accuracy of risk assessment models could be improved with inclusion of mental health parameters But what is the effort reward? May assist in setting accurate threshold targets for determining allocation of resources Requires validation in: larger samples, men, using proxy markers/self-reported measures

Implications Greatest victories in cardiology occurred through prevention targeting putative risk factors Smoking Blood pressure Advances in pharmacotherapy? Mental health Composite approaches to prevention & treatment are warranted

Acknowledgements All GOS study participants GOS Project Team GOS Investigator team Stanford University NHMRC Deakin University Central Grants Fund & Co-Investigators, especially Dr Aaron Fisher UC Berkeley for statistical analyses

Email: adrienne.oneil@unimelb.edu.au Twitter: @DrAdrienneOneil Copyright The University of Melbourne 2011